|Bid||0.2350 x N/A|
|Ask||0.2400 x N/A|
|Day's Range||0.2350 - 0.2500|
|52 Week Range||0.0250 - 0.4600|
|Beta (5Y Monthly)||-0.68|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - Revive Therapeutics (CSE: RVV) (OTC PINK: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, has signed a supply agreement with Havn Life Sciences Inc.For more information, please view the InvestmentPitch Media "video" which provides additional information about this news and the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter ...
Expanding research and development of naturally-derived psilocybin for future FDA IND-enabling and clinical studiesTORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has signed a supply agreement (the “Agreement”) with Havn Life Sciences Inc. (CSE : HAVN) (FRA: 5NP) (“Havn Life”) to source naturally-derived psychedelic compounds, such as psilocybin, for use in future investigational new drug (“IND”) enabling studies and clinical trials under the Food and Drug Administration (“FDA”) guidelines. "We are excited about our strategic partnership with Havn Life as one of our suppliers of psychoactive compounds that we intend to develop and commercialize using our established tannin-chitosan based proprietary oral-thin film delivery system, for the pharmaceutical and wellness markets,” said Michael Frank, Revive’s Chief Executive Officer. “We are developing unique products with both synthetic and naturally-derived psilocybin and building relationships with companies and institutions that support our objectives in the psychedelic space including our established relationship with the University of Wisconsin-Madison in the research and clinical development of our novel Psilocybin oral-thin film product and the Phase 1 clinical study using psilocybin in the treatment of methamphetamine use disorder.”Havn Life Sciences is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds.Susan Chapelle, Co-CEO, Havn Life added: “Our path at Havn Life has always been very clear: to supply standardized, quality controlled compounds to researchers so they can do the research that’s necessary to document health and wellness benefits of psychedelic medicine and ultimately help the industry with the knowledge required to legalize these compounds. We are thrilled to have signed this supply agreement with Revive Therapeutics to help further their work in this field. Both of our companies are leading innovators in the space, and we look forward to helping Revive achieve their goals with our compound supply.” Revive’s Psilocybin Oral Thin-film ProductUnder its sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison, the Company is developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity. There are a number of advantages and benefits of an orally dissolvable psilocybin thin film such as the rapid dissolving and onset of action to the bloodstream, the ease and convenience for patients to administer without the need of water, chewing or swallowing, the potential of improved therapeutic outcomes and efficacy for underserved diseases and disorders including the flexibility to create accurate dosing and tasteful options. The Company’s delivery technology is a natural, non-toxic, biodegradable and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties. The delivery technology has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.Revive’s Clinical Study of Psilocybin in the Treatment of Methamphetamine Use DisorderThe Company has entered into a Clinical Trial Agreement with the Board of Regents of the University of Wisconsin System to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.” The Phase I study Principal Investigator is Dr. Christopher R. Nicholas, Ph.D., Assistant Professor of Program for Research Outreach Therapeutics and Education in the Addictions in the Department of Family Medicine and Community Health at University of Wisconsin School of Medicine and Public Health. The clinical study will be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health, and School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin. The Company will have exclusive access to key intellectual property from this study.About Revive Therapeutics Ltd.Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.For more information, please contact:Michael Frank Chief Executive Officer Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: firstname.lastname@example.org Website: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.Cautionary StatementThis press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2019, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com.
OTCStockReview.com News CommentaryATLANTA, Oct. 16, 2020 (GLOBE NEWSWIRE) -- 2020 has been quite a year, but hidden among the carnage is great news about advances in research on psychedelic medicine to treat mental health issues. In January Johns Hopkins announced it had launched the Center for Psychedelic and Consciousness Research three months earlier. With $17 million in private funding and a full panel of planned studies, Johns Hopkins' researchers planned to focus on how psychedelics impact brain function and mood in both healthy individuals and those affected by mental health issues. What John Hopkins did not realize is that it would be sparking the psychedelic revolution. Psychedelics, like psilocybin, are garnering interest from mainstream America. Denver, Oakland, and Santa Cruz have recently legalized its use. Ann Arbor, Michigan lawmakers voted to decriminalize psilocybin mushrooms and a ballot in Oregon could legalize its use by November 2020. This paradigm-shift in the treatment of mental health disorders could be the single best thing to come out of 2020. As researchers and the medical community develop more valuable tools for understanding the brain’s connection to mind and behavior, millions of people all over the world will benefit. Numerous studies on psychedelics are already proving such treatments can treat a host of mental issues, like obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. As clinical trials supporting psychedelic treatments begin to prove the theories of researchers, we would expect to see big pharmaceutical companies investing heavily into psychedelics for their own drug pipelines.In our opinion, this opens up significant opportunities for investors to profit from psychedelic stocks in the coming months. A few companies to put on your radar screen are COMPASS Pathways (NASDAQ:CMPS), Mind Medicine Inc. (OTC: MMEDF), Ehave, Inc. (OTC: EHVVF), and Revive Therapeutics Ltd. (OTC Pink: RVVTF).COMPASS Pathways (NASDAQ:CMPS) came public on the NASDAQ at $17.00 a share on September 18th, 2020, making it the first psychedelic company to be listed on a U.S. exchange. Since then, CMPS shares have traded as much as 160% above the offering price, providing investors with a tremendous short-term return. CMPS did more than provide investors with a huge return; it also alerted a whole new crop of investors to psychedelic medicine stocks. Co-founded by George Goldsmith and Ekaterina Malievskaia, COMPASS Pathways added Lars Christian Wilde and went to work developing psilocybin (the active compound in magic mushrooms) for use in patients with treatment-resistant depression. COMPASS Pathways is currently conducting an FDA phase IIb clinical trial of psilocybin therapy for treatment resistant depression in 20 sites across Europe and North America. The Company expects to have results in 2021.COMPASS Pathways is based in London, UK and the Company is pioneering the development of a new model of psilocybin therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA) for treatment-resistant depression (TRD). H.C. Wainwright analyst Patrick Trucchio initiated coverage on COMPASS Pathways October 14, 2020 with a Buy rating and set a price target of $65.00. Canaccord Genuity also initiated coverage with a Buy rating on the stock with an $80.00 price target. www.compasspathways.comEhave, Inc., (OTC Pink: EHVVF) is making its mark in the psychedelic medicine space as a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Ehave's proprietary Dashboard utilizes BlockChain technology to provide better communication among health care providers for better patient outcomes and is compliant with both HIPAA and GDPR standards. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. With an interest in psychedelic research, Ehave's Dashboard offers the medical and research community an opportunity to share information with an emphasis on security. The Ehave Dashboard has been developed through years of testing with mental healthcare professionals at one of Canada’s largest hospitals, Toronto’s Hospital for Sick Children. In addition to providing better outcomes, the proprietary platform allows individuals to take control of their physical and mental health by enabling them to carry their medical records with them wherever they go.Ehave also owns a piece of the PsyTech Summit , which brings together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. As a result of the Covid-19 pandemic, the PsyTech Summits are being held virtually, but still cater to thousands of virtual attendees, as well as live guests at select city hubs across four continents. PsyTech Summit 2020 will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Register free at https://www.psytech.biz. Speakers for the conference include Dr. Julie Holland who is a psychiatrist, psychopharmacologist, and author of the New York Times bestseller Moody Bitches and Weekends at Bellevue; David Nutt who is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Hammersmith Hospital, Imperial College London; Dr. Beatriz Caiuby Labate (Bia Labate) who is the Executive Director of the Chacruna Institute for Psychedelic Plant Medicines; Rick Doblin, Ph.D. who is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS); and Del Joly former business development for Charlotte’s Web. www.ehave.comMind Medicine (OTCQB: MMEDF) made the last big splash in the psychedelic medicine pool. The Company raised $24 Million in a pre IPO round which included Kevin O’Leary and Bruce Linton, a founder of Canopy Growth Corporation. Since coming public the stock has more than doubled. Mindmed listed in March on the Canadian NEO exchange and here in the US on the Other OTC. The shares now trade on the OTCQB. Since then MindMed has moved beyond ketamine and psilocybin mushrooms and now looking towards LSD (lysergic acid diethylamide) as a treatment compound. MindMed has started clinical trials for LSD to treat anxiety and cluster headaches, as well as clinical trials for MDMA (3,4 Methylenedioxymethamphetamine) and DMT (the active ingredient in Ayahuasca). The company is planning to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. MindMed applied for an up-listing on the NASDAQ on September 21, 2002, just days after Compass Pathways went public.On October 9, 2020 MindMed announced a $25 million bought deal public offering. The press release announcing the capital raise was not supposed to be released in the U. S., but since the OTCQB symbol is in there, it was hard to miss. A bought deal is a securities offering usually done in Canada in which an investment bank assumes the risk of committing to buy the entire offering from the client company. Canaccord Genuity Corp. acted as the lead underwriter, and Canaccord Genuity Corp. analyst Tania Gonsalves said in a recent report that psychedelic medicines and psychedelic-assisted therapy could become a $100 billion market. www.mindmed.coRevive Therapeutics Ltd. (OTC Pink: RVVTF) is an Ontario, Canada based life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.In February, RVVTF announced plans to acquire Psilocin Pharma Corp. for $2.75 million. Psilocin has developed production solutions for the active compound Psilocybin. The precisely dosed formulations work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to eventually Food and Drug Administration approval in the treatment of conditions such as depression, anxiety, bi-polar disorder, bulimia and anorexia. The company also filed an IND for a COVID treatment. www.revivethera.comDISCLAIMER: OTC Stock Review (OTCSR), which owns and operates OTCStockReview.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. OTCSR is NOT affiliated in any manner with any company mentioned herein. OTCSR and its affiliated companies is a news dissemination solutions provider and are not a registered broker/dealer/analyst/adviser. OTCSR holds no investment licenses and may not sell, offer to sell or offer to buy any security. OTCSR's market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. OTCSR is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed OTCSR was compensated one thousand five hundred dollars for news coverage of current press releases issued by Ehave, Inc. by a non-affiliated third party. OTCSR HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCSR undertakes no obligation to update such statements.Contact Information:David Kugelman(404) 856-9157 Office(866) 692-6847 Toll Free - U.S. & Canadadk@otcstockreview.comhttps://www.linkedin.com/in/davidkugelman